At High-risk for Pre-eclampsia After Assisted Reproductive Technology
The overarching goal of the project is to unravel PE etiopathogenesis in high-risk patients (PCOS patients and oocyte acceptors) after assisted reproductive technology (ART) to individualize prenatal care following ART and to determine potential targets for new PE prevention options decreasing the morbidity/mortality caused by this pathology. More specifically, the following objectives/work packages (WPs) are put forward: * WP1 - PRECONCEPTION: Identify preconceptional maternal characteristics associated with in-creased risk of PE in ART patients (1a) and investigate the potential role of the endometrium prior to pregnancy (1b). * WP2 - DURING PREGNANCY: Evaluate the Fetal Medicine Foundation's (FMF) first trimester PE screening in selected high-risk groups post ART to explore the clinical benefit in this specific context (2a) and investigate the association between parameters during the pregnancy and PE development post-ART. * WP3 - AT DELIVERY: Identifying placental molecular pathways associated with PE post-ART.
• First time oocyte acceptors Or Nulliparous PCOS patients undergoing ART (IVF/ICSI)
• Criteria for PCOS: two out of the three following criteria must be present:
‣ Oligo-or anovulation: a menstrual cycle \>35 days
⁃ Hyperandrogenism:
• Clinically: the presence of hirsutism and/ or severe acne in combination with alopecia confirmed hyperandrogenism Or
∙ Biochemically: serum total testosterone \>52 ng/dl or calculated free testosterone \>0,64 ng/dl
⁃ Polycystic ovaries:
• Follicle number per ovary (FNPO) ≥ 12 on both ovaries Or
∙ Ovarian volume ≥ 10 ml in both ovaries Or
∙ One ovary with ≥ 20 follicles (Using endovaginal US transducers with a frequency bandwidth that includes 8 MHz) Or
∙ AMH ≥ 4,9 ng/ml